#4-24E. Steroids and Survival in ICI-Arthritis (ARD, 2026)

Does treating immune checkpoint inhibitor-associated inflammatory arthritis (ICI-IA) with glucocorticoids compromise a patient's cancer progression-free survival (PFS)? In today's episode, we delve into a prospective multicenter study from the RADIOS registry that analyzed 269 cancer patients with ICI-IA to evaluate the impact of glucocorticoid therapy on their oncological outcomes. The most critical finding of this research demonstrates that low-dose oral glucocorticoids—specifically a median prednisone-equivalent dose of 13 mg per day prescribed during the first month of treatment—do not adversely affect PFS. This highlights a pivotal clinical point: the relatively low steroid doses typically prescribed by rheumatologists appear oncologically safe. However, when critically appraising this study, clinicians should be mindful of potential survivor bias, as patients had to survive long enough on immunotherapy to develop arthritis and receive a rheumatology referral, alongside the inherent heterogeneity of the cancer types involved. Ultimately, this paper is highly significant for physicians because it provides evidence-based reassurance that they can safely alleviate debilitating immune-related joint symptoms with low-dose steroids without fearing a negative impact on the patient's underlying cancer progression.

Citation: Jannat-Khah DP, et al. Oral glucocorticoid treatment for checkpoint inhibitor-associated inflammatory arthritis does not affect cancer progression-free survival: a RADIOS Registry study. Annals of the Rheumatic Diseases. 2026. DOI: 10.1016/j.ard.2026.02.017

Disclaimer: This audio summary is based on personal interpretation and does not guarantee the exact content of the original paper. Please refer to the original article for details.